SVA
NASDAQ · Biotechnology
Sinovac Biotech Ltd
$6.47
+0.00 (+0.00%)
Financial Highlights (FY 2026)
Revenue
445.10M
Net Income
-99,209,845
Gross Margin
59.5%
Profit Margin
-22.3%
Rev Growth
-4.3%
D/E Ratio
0.03
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | |
|---|---|---|
| Gross Margin | 59.5% | 59.5% |
| Operating Margin | -134.5% | -121.1% |
| Profit Margin | -22.3% | -21.2% |
Income Statement
| FY 2026 | FY 2025 | |
|---|---|---|
| Revenue | 445.10M | 464.96M |
| Gross Profit | 264.88M | 276.70M |
| Operating Income | -598,754,125 | -562,915,191 |
| Net Income | -99,209,845 | -93,271,555 |
| Gross Margin | 59.5% | 59.5% |
| Operating Margin | -134.5% | -121.1% |
| Profit Margin | -22.3% | -21.2% |
| Rev Growth | -4.3% | -4.3% |
Balance Sheet
| FY 2026 | FY 2025 | |
|---|---|---|
| Total Debt | 9.08M | 9.08M |
| Total Equity | 310.87M | 310.87M |
| D/E Ratio | 0.03 | 0.03 |
Cash Flow
| FY 2026 | FY 2025 | |
|---|---|---|
| EBITDA | -94,749,309 | -94,026,787 |
| Free Cash Flow | — | — |